CTRI/2022/03/041441尚未招募未知
effect of inhaled nitrous oxide on induction time and dose requirement of propofol a prospective randomised study
Dr Mankeerat Kaur0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •American society of anaesthesiologists (ASA) 1 and 2
- •age range 18-60
- •any elective minor or major surgery requiring general anaesthesia
排除标准
- •morbid obesity
- •bronchial asthma
- •diabetes mellitus
- •drug allergy
- •relative contraindications ( intestinal obstruction, middle ear disease, pneumothorax, air embolism)
研究者
相似试验
进行中（未招募）
不适用
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD)Implantation. - INOT41acute right ventricular failureMedDRA version: 9.1Level: LLTClassification code 10063082Term: Acute right ventricular failureEUCTR2005-000326-24-DEINO Therapeutics110
进行中（未招募）
1 期
The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD) Implantation. - INOT41EUCTR2005-000326-24-GBINO Therapeutics110
尚未招募
3 期
Comparison of Intraurethral lidocaine gel with and without nitrous oxide and oxygen mixture inhalation on rigid cystoscopy for pain managementInclusion Criteria1.Patient who was performed by use rigid cystoscopy size 22 Fr2.Patient who was performed by use rigid cystoscopy size 22 Fr with tissue biopsy at bladder mucosa3.Patient who was performed by use rigid cystoscopy size 22 Fr with ureteral insertion size 6 Fr4.Femal and male patients age above 18 Yrs oldCystoscopyEntonoxPainTCTR20211106001/A54
已完成
不适用
The effect of nitrous oxide on intracuff pressure and complication when using LMA protector™Diseases of the musculo-skeletal system and connective tissueKCT0004978Myongji Hospital92
进行中（未招募）
1 期
The Effects of Nitric Oxide for Inhalation on the development of chronic lung disease in pre-term infants. - INOT-27Prevention of chronic lung disease in pre-term infants ( gestational age < 29 weeks) with respiratory distress.MedDRA version: 7.0 Level: LLT Classification code 10054933EUCTR2004-002312-29-GBINO Therapeutics800